Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19...

Area of Science:

• Immunology
• Oncology
• Microscopy

Background:

• Chimeric antigen receptor T-cell (CAR-T) therapy is being investigated for multiple myeloma.
• CD19 CAR-T therapy has shown remissions, but CD19 expression is typically low and hard to detect by flow cytometry (FC).

Purpose of the Study:

• To investigate CD19 expression on multiple myeloma cells using a highly sensitive microscopy technique.
• To determine the threshold for CAR-T efficacy against cells with low antigen density.
• To explore the utility of super-resolution microscopy in guiding immunotherapy patient selection.

Main Methods:

• Direct stochastic optical reconstruction microscopy (dSTORM) was employed to quantify CD19 expression on myeloma cells at a single-molecule level.
• In vitro experiments assessed the efficacy of CD19 CAR-T cells against myeloma cells with varying CD19 densities.
• Similar analyses were performed for CD20 expression and CD20 CAR-T cells.

Main Results:

• dSTORM detected CD19 expression on 10.3-80% of myeloma cells in 10 out of 14 patients, with densities ranging from 13 to 5,000 molecules per cell.
• FC detected CD19 in only 2 of these 10 patients, on a smaller cell fraction.
• CD19 CAR-T effectively eliminated myeloma cells expressing fewer than 100 CD19 molecules, demonstrating efficacy against ultra-low antigen levels.

Conclusions:

• Super-resolution microscopy (dSTORM) significantly enhances the detection of antigens like CD19 on multiple myeloma cells compared to FC.
• CAR-T therapy can eliminate myeloma cells even with very low target antigen expression, establishing a sensitivity threshold.
• Advanced imaging techniques can guide patient selection for immunotherapies targeting antigens with ultra-low expression densities.